Core Viewpoint - The 18th China Scientific Instrument Development Annual Conference (ACCSI2025) is set to take place on May 11, 2025, at the Shanghai Fuyue Hotel, showcasing significant developments and opportunities in the scientific instrument industry [1][2]. Group 1: Event Overview - The conference will feature a welcoming banner and various activities, attracting participants from across the country [2]. - The event spans two and a half days, focusing on the scientific instrument industry [2]. Group 2: Forums and Awards - On May 11, the conference will host the 6th Scientific Instrument CMO Summit Forum and the 5th Strategic Development Symposium, with hundreds of industry leaders and experts in attendance [20]. - An award ceremony will take place on the evening of May 12, recognizing outstanding products and contributions in the industry, with live streaming for those unable to attend [23].

Core Viewpoint - The article emphasizes the significance of spatial omics and mass spectrometry imaging (MSI) technology in clinical diagnostics and precision medicine, highlighting its potential for future research and applications [2][3]. Group 1: Spatial Omics and MSI Technology - In 2022, Nature recognized spatial omics as one of the seven most promising technologies, showcasing its potential in life sciences [3]. - MSI technology offers remarkable multi-scale visualization capabilities, enabling molecular spatial localization and qualitative analysis from whole organisms to single cells [3]. - This technology reveals the specific distribution of molecules within biological systems and provides critical information on the relationship between molecular function and spatial location, aiding in the understanding of biochemical processes and the roles of molecules in physiological and pathological mechanisms [3]. Group 2: Future Prospects of MSI Technology - The future of MSI technology appears promising, with a focus on high-throughput detection and precise identification at the single-cell level [4]. - MSI is expected to evolve into a new generation of molecular pathology diagnostic technology, contributing to the advancement of precision medicine through interdisciplinary and multi-technology integration [4]. - The integration of artificial intelligence (AI) with MSI is anticipated to enhance ion recognition and analysis efficiency, facilitating the development of new principles in mass spectrometry [4]. Group 3: Upcoming Events and Contributions - Professor Repaal Abulizi will present at the 18th China Scientific Instrument Development Annual Conference (ACCSI 2025) in Shanghai, sharing insights on MSI technology [4]. - The conference aims to promote healthy and rapid development in the scientific instrument industry, providing a platform for effective communication among various stakeholders [11].

特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 仪粉e r们，今天是高薪精品仪器职位专辑，有不少 新的雇主 哦！ 销售精英，热招职位 Ho t r e c r u itme n t p o siti o n s 安捷伦科技（中国）有限公司 Ch a n n e l Sa l e s 病理业务 IVD 广州- 2 0 k - 3 0 k · 1 3薪 岗位要求： （分析化学、化学、化工、制药、仪器设备、电子电路、环境工程、食品科学等相关专业）或仪器等 本科及以上学历，学习能力 强。 常州磐诺仪器有限公司 色相气质销售 重庆- 8 k - 1 2 k · 1 3薪 岗位要求： 具有一定理工科背景（分析化学、化工、检验检疫、仪器设备、电子电路、环境工程、食品科学等相关专业优先）；具有良好的语 言表达、沟通及组织及协调能力。 天美仪拓 实验室产品销售 杭州- 8 k - 1 0 k · 1 3薪 岗位要求： 大专及以上学历，生物、医药或生命科学相关专业，3年以上市场销售相关工作经验；出色的谈判技巧和沟通能力。 岛津（上海）实验器材有限公司 ...

Core Viewpoint - The integration of AI into scientific instruments is transforming them from precise tools into intelligent entities, driving a revolution in productivity and innovation across various sectors [2][4]. Group 1: AI's Impact on Scientific Instruments - AI is enhancing the capabilities of scientific instruments, enabling features such as automatic parameter calibration in spectrometers and real-time ecological data analysis in environmental monitoring [3][4]. - The application of AI allows for smarter decision-making and optimization in scientific research, manufacturing processes, and data analysis, significantly reducing trial-and-error costs [3][4]. Group 2: Upcoming Forum Details - The "ACCSI 2025 Artificial Intelligence and Scientific Instruments Integration Development Forum" will take place in Shanghai on May 12-13, 2025, focusing on AI-driven innovations in scientific instruments [4][20]. - The forum will feature discussions on AI's role in advancing spectrometry and chromatography, with participation from over 20 leading experts from various sectors [4][5]. Group 3: Expert Contributions - Notable speakers include Professor Ouyang Wanli from Shanghai AI Laboratory, who will discuss the new ecosystem of high-end instrument development empowered by AI [4][8]. - Other experts will cover topics such as AI in environmental instrument development, non-invasive blood glucose detection, and the integration of AI in food safety monitoring [7][10]. Group 4: Industry Transformation - AI is not just a tool for efficiency but a catalyst for interdisciplinary innovation, reshaping how scientific instruments are developed and utilized across different fields [4][5]. - The forum aims to explore how traditional instrument companies can build new competitive advantages through AI integration in manufacturing and operational processes [5][6].

Investment Rating - The report maintains an "Outperform" rating for the company [2] Core Insights - The company reported a revenue of 310 million yuan in 2024, a decrease of 9.1% year-on-year, and a net profit of 13 million yuan, down 71.0% year-on-year, which was below expectations [7] - In Q1 2025, the company achieved a revenue of 55 million yuan, an increase of 37.8% year-on-year, although it reported a net loss of 1 million yuan [7] - The company is expected to benefit from government policies aimed at promoting equipment updates and increasing technology spending, which could lead to a recovery in demand [7][10] Financial Data and Profit Forecast - The company’s total revenue is projected to be 342 million yuan in 2025, with a year-on-year growth rate of 10.2% [6] - The net profit forecast for 2025 is 43 million yuan, representing a significant increase of 230.5% compared to 2024 [6] - The company’s gross margin is expected to be 65.6% in 2025, slightly improving from 64.3% in Q1 2025 [6] Revenue Breakdown - In 2024, the company’s revenue from organic element analysis was 104 million yuan, down 23.0% year-on-year, while sample preparation revenue was 57 million yuan, down 18.7% [7] - The chromatography and spectroscopy segment generated 79 million yuan, with liquid chromatography instruments contributing 46 million yuan, an increase of 27.2% year-on-year [7] - The company’s international revenue reached 70 million yuan in 2024, up 12.2% year-on-year, driven by expanded overseas distribution channels [7] Strategic Initiatives - The company has been investing in automation and digitalization since 2014, enhancing its manufacturing capabilities [10] - The introduction of a digital core platform in 2024 is expected to support the production of customized non-standard components [10] - The report highlights the company’s proactive approach in recruiting high-quality talent during industry downturns to ensure long-term growth [7][10]

Core Viewpoint - The 18th China Scientific Instrument Development Annual Conference (ACCSI 2025) will be held from May 11-13, 2025, in Shanghai, focusing on the theme "Digital Intelligence Drives New Quality Leadership" [3]. Group 1: Event Overview - ACCSI 2025 aims to promote healthy and rapid development in the Chinese scientific instrument industry by providing a platform for effective communication among government, industry, academia, research, application, investment, and media [3]. - The conference has successfully held 17 sessions, with attendance exceeding 1,500 participants in a single session, earning the reputation of being the "Davos Forum" for the scientific instrument industry [3]. - The event will feature various activities, including keynote speeches, panel discussions, on-site seminars, and field visits, providing strategic decision-making references for industry development [3][4]. Group 2: Scheduled Activities - On May 12, there will be a CEO interview session focusing on reviewing highlights from 2024 and exploring market opportunities for 2025 [6]. - The ACCSI 2025 VIP Lounge will host discussions on the "Risks and Opportunities" in the scientific instrument industry for 2025 [6]. - Various exhibition tours will be organized, including special guest tours, buyer tours, and investment tours, allowing participants to engage directly with industry developments [8]. Group 3: Online Engagement - The event will also include rich online live streaming activities, enabling those unable to attend in person to experience the conference atmosphere and gain insights into industry trends [4]. - Participants can engage with the "AI Instrument" initiative at the Instrument Information Network booth, where they can receive a complimentary photo by following the official account and sharing on social media [8].

Core Viewpoint - The company is actively engaging in the high-end scientific instrument market, focusing on product development, market expansion, and optimizing financial health while addressing challenges posed by competition and market dynamics [1][2][3]. Group 1: Business Development and Market Position - The company has established several business units in the life sciences sector, including Pujing Medical and Pukang Medical, to address clinical research and early disease diagnosis needs [2]. - The company aims to enhance its market competitiveness through technological breakthroughs and partnerships, particularly in the high-end scientific instrument sector [2][3]. - The company is focusing on optimizing its asset-liability structure, with a current debt ratio of 63.64% and accounts receivable amounting to 838 million [3][4]. Group 2: Financial Performance and Strategy - The company reported a net cash flow from operating activities growth of 152.34% year-on-year, with a current liquidity ratio of 1.17 and a quick ratio of 0.8 [4]. - The company plans to reduce its debt levels and improve cash flow management to enhance financial stability and investor confidence [3][4]. - The company is committed to increasing R&D investment in high-end mass spectrometry and environmental monitoring technologies to maintain its competitive edge [3][4]. Group 3: International Expansion and Market Trends - The company has successfully signed contracts for its ProGC-3600 industrial online gas chromatography analyzer in international markets, including Vietnam [3]. - The company is expanding its overseas business in regions such as Europe, Asia, North America, and Africa, with five subsidiaries established in the Netherlands and Italy [3][4]. - The global market for analytical instruments is projected to grow, with the Chinese market experiencing rapid growth, presenting opportunities for the company to increase its market share [22]. Group 4: Technological Innovation and Product Development - The company is leveraging AI technology to enhance its environmental management solutions, integrating advanced monitoring equipment for various applications [11][18]. - The company is focused on achieving full domestic production capabilities for its key components, ensuring independence from foreign suppliers [12][18]. - The company is committed to continuous product improvement and customer engagement to enhance its offerings in the life sciences sector [22].

Financial Data and Key Metrics Changes - Bruker reported revenues increased by 11% year over year to $801.4 million, exceeding the preannounced range of $795 million to $800 million [11][36] - Constant exchange rate (CER) revenue growth was 12.5% year over year, with organic growth of 2.9% [11][36] - Non-GAAP operating margin was 12.7%, down year over year due to expected M&A dilution from strategic acquisitions [11][39] - Non-GAAP diluted EPS was $0.47, down from $0.53 in Q1 2024, primarily due to foreign exchange headwinds [12][39] Business Line Data and Key Metrics Changes - BioSpin revenue was $208 million with mid-teens percentage CER growth, driven by strong biopharma performance [12] - CALID group had revenue of €280 million with mid-20s percentage CER growth, led by microbiology and infection diagnostics [13] - Bruker Nano revenue was $257 million with high single-digit percentage CER growth, supported by inorganic revenue growth from NanoString [14] - BEST segment CER revenues declined in the high teens percentage due to weaker performance in the Research Instruments business [14] Market Data and Key Metrics Changes - Americas revenue declined in the low single digits percentage, while European revenue grew in the mid single digits percentage [37] - Asia Pacific revenue grew in the low single digits percentage despite a 10% decline in China [37] - EMEA region revenue was up mid-teens percentage [37] Company Strategy and Development Direction - Bruker launched innovative products in spatial biology, cellular analysis, NMR, microbiology, and molecular diagnostics, enhancing its strategic focus [9] - The company anticipates that post-genomic innovations will drive continued higher revenue CAGR differentiation beyond current headwinds in the U.S. and China [9] - Management is implementing cost initiatives, new pricing actions, and supply chain reengineering to mitigate headwinds from U.S. policy changes and tariffs [20][32] Management's Comments on Operating Environment and Future Outlook - Management expects U.S. academic government revenue to decline by 20% to 25% due to research funding policy changes [24] - The company anticipates a gross headwind of approximately €100 million to organic revenues in fiscal year 2025 from recent policy changes and tariffs [21] - Management remains optimistic about transforming Bruker's portfolio for above-market revenue growth and margin expansion once headwinds abate [46] Other Important Information - The company generated $65 million of operating cash flow in Q1 2025, with free cash flow of $39 million [40] - Updated fiscal year 2025 revenue guidance is $3.48 billion to $3.55 billion, reflecting reported growth of 3.5% to 5.5% [41] - Non-GAAP EPS guidance for 2025 is in the range of $2.40 to $2.48, translating to roughly 0% to 3% growth compared to 2024 [43] Q&A Session Summary Question: Was there any pull forward in the quarter due to tariffs? - Management indicated there was no significant pull forward due to tariffs, although a smooth installation helped Q1 slightly [51][53] Question: How are offsets from AI chips and funding initiatives being considered? - Management noted strong demand for AI tools and potential benefits from German and Korean stimulus funding, but these are expected to have a more significant impact in 2026 and beyond [59][62] Question: How will Bruker offset potential U.S. budget cuts next year? - Management highlighted various growth drivers, including biopharma and European investments, while acknowledging the need to navigate current headwinds [70][72] Question: What is the current state of the order book and backlog? - Management reported a slight decline in the order book year over year, with a backlog of approximately seven months, indicating a buffer for future quarters [78][79] Question: Can you elaborate on pricing and manufacturing initiatives to offset tariffs? - Management is implementing pricing actions and exploring onshoring production to mitigate tariff impacts, with significant cost actions already underway [85][90]

Financial Data and Key Metrics Changes - Bruker's Q1 2025 reported revenues increased 11% year over year to $801.4 million, exceeding the preannounced range of $795 million to $800 million [9][33] - Non-GAAP operating margin for Q1 2025 was 12.7%, down year over year due to expected M&A dilution from strategic acquisitions [9][35] - Diluted non-GAAP EPS for Q1 2025 was $0.47, down from $0.53 in Q1 2024, primarily due to FX currency headwinds [10][36] Business Line Data and Key Metrics Changes - BioSpin revenue was $208 million with mid-teens percentage CER growth, driven by strong biopharma performance [10] - CALID group had revenue of €280 million with mid-20s percentage CER growth, led by microbiology and infection diagnostics [11] - Bruker Nano revenue was $257 million with high single-digit percentage CER growth, supported by inorganic revenue growth from NanoString [12] Market Data and Key Metrics Changes - Americas revenue declined in the low single digits, while European revenue grew in the mid single digits, and Asia Pacific revenue grew in the low single digits despite a 10% decline in China [34] - EMEA region revenue was up mid-teens percentage, indicating strong performance in that market [34] Company Strategy and Development Direction - The company launched innovative products in spatial biology, cellular analysis, NMR, microbiology, and molecular diagnostics, aiming to strengthen high-value offerings [7] - Bruker anticipates that post-genomic innovations will drive continued higher revenue CAGR differentiation beyond current headwinds in the U.S. and China [7] - The company is implementing cost initiatives, new pricing actions, and supply network reengineering to mitigate headwinds from U.S. policy changes and tariffs [29][30] Management's Comments on Operating Environment and Future Outlook - Management expects U.S. academic government revenue to decline by 20% to 25% in 2025 due to funding uncertainties [22][23] - The company anticipates a gross headwind of approximately €100 million to organic revenues in 2025 from policy changes and tariffs [19] - Management remains optimistic about long-term growth, expecting to resume margin expansion and strong EPS growth in 2026 and beyond [42] Other Important Information - The company generated $65 million of operating cash flow in Q1 2025, with free cash flow of $39 million reflecting improved working capital performance [37] - Updated guidance for fiscal year 2025 includes reported revenues of $3.48 billion to $3.55 billion, representing growth of 3.5% to 5.5% [38] Q&A Session Summary Question: Was there any pull forward in the quarter due to tariffs? - Management indicated there was no significant pull forward due to tariffs, although a smooth installation contributed positively to Q1 [49][50] Question: How does the company plan to offset potential budget cuts in the U.S.? - Management highlighted several growth drivers, including biopharma, AI, and European defense spending, which could help offset budget cuts [66][68] Question: What is the current status of the order book and backlog? - The order book was slightly down year over year, but the backlog remains strong at around seven months, providing a buffer for future quarters [73][104]

导读： 第十八届中国科学仪器发展年会ACCSI2025 将于5月11-13日在上海市松江区举行，参会指南提供签到注册流程、会议日程、 交通及酒店信息等。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 尊敬的特邀嘉宾和参会代表： 2 0 2 5第十八届中国科学仪器发展年会(ACCSI 2 0 2 5 )将于2 0 2 5年5月11 - 1 3日在上海市松江区富悦大酒店隆重召开。为 方便各位特邀嘉宾和参会代表顺利参加会议，组委会为大家提供如下参会指南。 一、 签到注册流程 1、注册时间： 2 0 2 5年5月1 2日 0 8 : 0 0 - 2 0 : 0 0 2 0 2 5年5月1 3日 0 8 : 0 0 - 1 4 : 0 0 2、注册位置： 上海市松江区富悦大酒店一楼大厅左侧签到处 3、注册流程： 获取签到二维码： 仪器信息网APP ACCSI 2 0 2 5年会官网 2 0 2 5年5月11日 1 0 : 0 0 - 2 0 : 0 0 二、 会议日程 | 日期 | 时间 | 会议日程 | 地点 | | --- | --- | -- ...